Silvia L. Caimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Silvia L. Caimi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anny Schäfer
Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
1 shared publication - Bruno Sempere
Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
1 shared publication - Bérengère Renault
Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
1 shared publication - Diego Freti
Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
1 shared publication - Eric S. White
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut
1 shared publication François Le Goff
Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
1 shared publication
Latest Publications
- Open Access
- 8 February 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (3)
NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model
In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in “HAS1 High FB” and “PLIN2+ FB” populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α–smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.
- 8 February 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (3)
Open AccessNF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model
In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in “HAS1 High FB” and “PLIN2+ FB” populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α–smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.